APP and early-onset autosomal dominant Alzheimer disease: APP was selected for validation due its repeated association with various human neurodegenerative conditions, including but not limited to Alzheimer's disease (27), prion diseases (28), tauopathies (29), murine neurodegenerative disease models, and as part of an acute phase response to neuronal injury (30).